MacuLogix Revenue and Competitors

Middletown, PA USA

Location

$64.3M

Total Funding

Estimated Revenue & Valuation

  • MacuLogix's estimated annual revenue is currently $2.1M per year.(i)
  • MacuLogix received $38.7M in venture funding in March 2019.
  • MacuLogix's estimated revenue per employee is $125,500
  • MacuLogix's total funding is $64.3M.

Employee Data

  • MacuLogix has 17 Employees.(i)
  • MacuLogix grew their employee count by -78% last year.

MacuLogix's People

NameTitleEmail/Phone
1
VP MarketingReveal Email/Phone
2
Director Product InnovationReveal Email/Phone
3
Sr. Director OperationsReveal Email/Phone
4
Director Software EngineeringReveal Email/Phone
5
Manager, Practice Management in Customer SuccessReveal Email/Phone
6
Manager LogisticsReveal Email/Phone
7
Sr. Manager, Professional RelationsReveal Email/Phone
8
Regional Sales ExecutiveReveal Email/Phone
9
Regional Sales ExecutiveReveal Email/Phone
10
President & CEOReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$73.5M29312%N/AN/A
#2
$7M28-10%N/AN/A
#3
$37.9M15113%N/AN/A
#4
$2.1M17-78%$64.3MN/A
#5
$9.3M37-10%N/AN/A
#6
$56.2M1790%N/AN/A
#7
$38.9M155-1%N/AN/A
#8
$22.1M885%N/AN/A
#9
$22.1M889%N/AN/A
#10
$33.4M13310%N/AN/A
Add Company

What Is MacuLogix?

MacuLogix is the only company to leverage the science of dark adaptation to help eliminate preventable blindness caused by AMD. Through its AdaptDx® dark adaptometer, MacuLogix enables eye care professional to detect, monitor and start treating AMD three years before it can be seen in order to prevent vision loss. MacuLogix provides in-practice training and best practices to support the effective and efficient implementation and use of the AdaptDx

keywords:Biotechnology,Healthcare,Medical Devices,Medical Diagnostics,Pharmaceuticals

$64.3M

Total Funding

17

Number of Employees

$2.1M

Revenue (est)

-78%

Employee Growth %

N/A

Valuation

N/A

Accelerator

MacuLogix News

2019-08-31 - Diagnose AMD earlier with dark adaptation testing

The AdaptDx (MacuLogix) is a functional testing device that has been shown in clinical trials to identify patients with the earliest stages of AMD even when they ...

2019-03-11 - MacuLogix adds $38.7 million in Series D financing

MacuLogix has completed $38.7 million in Series D financing led by Vivo ... of funding brings MacuLogix's venture funding total to $51 million.

2019-03-07 - Pennsylvania-Based Eye Care Company MacuLogix Raises $38.7 Million

MacuLogix, a Harrisburg, Pennsylvania-based company that equips eye care professionals with the instruments, tools, and education they need to effectively diagnose and treat patients with age-related macular degeneration (AMD), has raised $38.7 million in Series D funding. This round of funding ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.5M17N/AN/A
#2
$1M17-26%N/A
#3
$35M196%N/A
#4
$2.9M200%N/A
#5
$4.1M20-17%N/A

MacuLogix Funding

DateAmountRoundLead InvestorsReference
2013-03-12$3.6MAMultipleArticle
2015-08-04$5.0MUndisclosedArticle
2018-07-20$10.0MUndisclosedHorizon Technology Finance CorporationArticle
2019-03-05$38.7MDVivo CapitalArticle